GlassScriptPhysician profile
Thomas A Samaras
NPI 1821007550
$14,324.21
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,773 · 2020: $680 · 2021: $2,436 · 2022: $2,976 · 2023: $2,384 · 2024: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,460.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,457.43 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,841.79 | 2019-2024 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $1,575.08 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $1,047.78 | 2019-2024 | Spravato |
| Abbvie INC. | $825.19 | 2019-2024 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.74 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $720.84 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $656.59 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $523.94 | 2022-2023 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $411.93 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $378.34 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $374.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $295.68 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $283.02 | 2021 | |
| Merck Sharp & Dohme LLC | $272.77 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Samaras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.